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Abstract
Isaie Sibomana, M.S., Department of Biochemistry and Molecular Biology, Wright State
University, 2011
'Functional Metabolomics' Enhances Assessment of Tissue Dysfunction as Demonstrated
in a Rat Model of Sub-Acute D-serine Exposure

We describe a methodology that combines urinary metabolomics with a tissuespecific stressor administration to enhance assessment of tissue function. Kidney function
in rats was mildly compromised with a sub-acute dose of D-serine and stressed with
furosemide. NMR-based metabolomics analyses showed no detectable effects due to Dserine alone; but furosemide or D-serine + furosemide groups, classified separately from
each other, and from control. Furosemide alone caused a ca. 2-fold increase in glucose,
lactate, choline, and a 30% decrease in TCA intermediates (p≤0.05). D-serine suppressed
these effects and produced a 1.7-fold increase in a p-phenolic acid-derivative of tyrosine
(PAdY) relative to control (p≤0.05). The PAdY/tyrosine ratio increased 2-fold relative to
rats given furosemide alone. D-serine effects were only detectable in furosemidechallenged rats, suggesting that minor disruption in kidney function, induced by lowlevel D-serine,

is manifested by this functional metabolomics methodology. This

technique may improve sensitivity for assessment of tissue function and disease.
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1. INTRODUCTION
1.1 Overview on NMR-based metabolomics
Metabolomics (1, 2), which is also known as metabonomics (3, 4) or metabolic
profiling (5) is defined as the “quantitative measurement of the time-related multiparametric metabolic response of living systems to pathophysiological stimuli or genetic
modification” (3). NMR-based metabolomics has been used to associate an organism’s
health status to its metabolite profile measured in biofluids (e.g., urine, blood, fecal and
tissue extracts) or tissue biopsies. Coupled with multivariate data analyses, the 1 H NMRbased metabolomics approach is a fast, accurate and reproducible analytical technique for
visualization of biochemical changes in biofluids or tissues (3, 6-12). This methodology
involves correlating observed changes in metabolite levels to the biological effects
related to physiological stimuli or genetic modification, toxicological, pathophysiological
or environmental conditions.

The use of 1 H NMR-based metabolomics technique has

recently gained attention for direct application in preclinical, clinical, environmental and
biomedical areas (4) due to several advantages that the technique offers such as rapidity
and simplicity in sample preparation, high reproducibility and direct reflection of
biological events among others (13). Studies have highlighted its potential for the
successful identification and characterization of toxicity (14-25), metabolic pathways
perturbed in various cancers (26-33), disease-related stages in chronic lymphocytic
1

leukemia (34), and other pathophysiological conditions (10, 35). The power of this
technique is demonstrated for instance by its ability to detect the biochemical alterations
induced by drug/chemical exposure and precisely localize the target organ based on the
changes in metabolite concentrations observed from a peripheral sample such as urine or
blood (11). In fact, metabolomics constitutes an important tool required to give an insight
on the impact of various factors that affect the health status such as the genetic
modifications, exposure to stimuli (e.g., noxious agents, stressors, nutrients, etc),
toxicological, pathophysiological or environmental conditions (12).
1.2 Challenges for NMR-based metabolomics approach
Although the NMR-based metabolomics approach offers clear advantages in
health assessment and monitoring over the use of traditional clinical assays, it still has not
been widely implemented in clinical settings. One obstacle to clinical metabolomics
approaches is the fact that the metabolite profile of various biofluids is influenced by
numerous factors that may or may not be related to the biological processes of interest.
These include genetics (36), gender, age, nutrition (12, 37-39), disease processes,
environment, xenobiotics, (40, 41) and personal factors such as diet, exercise, and use of
medications, alcohol, tobacco, etc. (7). This high diversity, especially in humans,
produces a high “background noise” in metabolite profiles, which impedes data
interpretation.
task.

Thus relating metabolite profiles to health and disease is a formidable

Some of this variability can be minimized by controlling factors such as diet, or

imposing strict exclusionary criteria for subjects (i.e., exclude smokers or medications),
but this has been met with limited success due to numerous uncontrollable factors (422

44). Other methods attempt to examine the influence of perturbing factors on metabolite
profiles (7, 12, 45-47), but data are confounding and incomplete given the complexity of
the problem. A more promising approach involves longitudinal studies, which have
provided evidence that individual metabolic phenotypes may exist (48), and their
detection through multiple sample collection combined with advanced statistical methods
((49), and reference therein) may provide a means to eliminate the daily ‘metabolomics
noise’.
1.3 ‘Functional Metabolomics’ approach
Although several studies have successfully used NMR-based metabolomics to
point out differences in metabolite profiles inherent to gender, aging, nutrition (12, 3739), toxicity (14-16, 18-25, 43), diseases (10, 32, 34, 35) and other health-related issues,
there are various factors associated with human health conditions that may affect the
sensitivity of metabolomics assessment. Thus, to make this technique more useful, there
is a need to implement a well-designed approach that can enhance its sensitivity, which is
the basis of this study.
1.3.1 Hypothesis and Strategy for Functional Metabolomics
Herein we describe a different approach, dubbed functional metabolomics,
towards improving the sensitivity of metabolomics for detection of biologically relevant
effects. This methodology strives to increase the “signal-to-noise” ratio in metabolomics,
which may potentially improve its usefulness to measure real and meaningful biological
effects above the daily background variability. We hypothesize that the ability to detect
3

meaningful metabolite alterations, those related to tissue function/dysfunction, can be
greatly enhanced by applying an organ-specific “metabolic challenge”. The tissue
response under a metabolically stressed condition will reduce inter-animal variability,
and augment our capability to detect biologically relevant changes in urinary metabolite
profiles.

Detection of abnormalities (i.e., tissue dysfunction due to chemical exposure or

disease) will be enhanced when the stressor is applied. This approach is analogous to a
glucose tolerance test to check for diabetes. Here, glucose is given as a body’s metabolic
challenge and the body’s ability to clear the glucose from the blood reflects either normal
or altered insulin sensitivity.
We tested this hypothesis in a rat model, using kidney as the target organ and
furosemide, a diuretic drug, as an exogenous metabolic challenge (tissue stressor).
Further, we compared normal healthy animals to animals that were exposed to a subacute dose of D-serine, a well-characterized nephrotoxin. This low-dose D-serine
exposure was undetectable by standard urinary metabolomics analyses. But the mild
kidney dysfunction in D-serine-treated animals was revealed under the furosemideinduced

(kidney-stressed)

condition.

Theoretically,

this

functional

metabolomics

methodology could be extended (1) to evaluate tissues or organ systems other than
kidney by developing tissue-targeted metabolic stressors, and (2) to detect tissue
dysfunction due to disease as well as exposure to xenobiotics.
1.3.2 Why D-serine in this study?
D-serine is a well-known kidney toxicant that was used in this study at a subacute dose to mildly disrupt kidney function. Several intensive studies have described the
4

nature of its toxicity in rat models (20-22, 50-52). D-serine is specifically re-absorbed
into the pars recta (or S3 straight segments) region of proximal tubules where the Damino acid oxidase (D-AAO) enzyme is localized (53). Proximal tubular necrosis can
develop as a result of excessive D-AAO enzymatic metabolism of D-serine, which can
generate reactive oxygen species and lead to a decrease in the levels of renal glutathione
(Figure 1) (54).
A study involving LEA/SENDAI rats that lack D-AAO enzyme highlighted the
role of this enzyme in D-serine-induced nephrotoxicity as these rats were not affected by
D-serine exposure when compared to their counterpart F344 rats which were
characterized by excessive excretion of glucose and urine after being exposed to the same
dose of D-serine (55). D-serine down-regulates various metabolic pathways such as the
TCA cycle through inhibition of citrate synthase enzyme (56), resulting in depletion in
citrate, α-ketoglutarate and succinate (22). D-serine has also been reported to have a
negative effect on oxidative phosphorylation, ATP synthesis coupled electron transport,
amino acid transport, metabolism of lipids, nucleotides, vitamins, carbohydrates and on
oxidative stress response (57). Other studies have also indicated that it induces an
increase in urinary excretion of glucose, lactate, acetate and alanine (22). The common
biomarkers of D-serine toxicity observed with rat models include proteinuria, amino
aciduria, glucosuria (Ganote et al., 1974; Carone & Ganote, 1975). The sub-acute dose of
D-serine used herein (60 mg/kg) was chosen based upon literature reports and
preliminary studies in our laboratory. Williams, et al. (21) found no observable
alterations in urinary metabolite profiles in Alderley Park rats exposed to 62.5 mg/kg Dserine. Additionally, studies in our laboratory (unpublished data) using Fischer-344 rats
5

showed no effects of D-serine at 50 mg/kg in comparison to 100 mg/kg, which was
characterized by glucosuria, proteinuria and amino aciduria. Thus, a dose of 60 mg/kg
D-serine was expected to be just below the threshold at which measureable effects can be
observed and was used in this study. At an effective dose, the maximal D-serine-induced
nephrotoxicity is observed within 24-48 h post exposure ((21); unpublished data from our
laboratory).

Figure 1. Mechanism for D-serine toxicity
1.3.3 Why Furosemide administration in this study?
Furosemide is a clinically used diuretic drug and was used here as a mild
chemical stressor targeting the kidney. Figure 2 shows its chemical structure (58).
Furosemide reversibly binds to Na+/2Cl-/K+ co-transport proteins in the thick ascending
6

limb of the loop of Henle, reducing the reabsorption of the salt and water, resulting in a
profound increase in urinary output (59-63). Other studies have suggested an extension of
furosemide effect to the distal tubules (64, 65). Furosemide is also reported to confer
renal protection by reducing oxygen requirement through the inhibition of the active
NaCl transport (66, 67). By inducing an increase in tubular blood flow, furosemide can
also drive a decrease in nephrotoxin concentrations (68).
The time at which furosemide was given to animals was made to coincide with 24
h post D-serine administration as our laboratory (unpublished data) and other studies (21,
52) have established that the maximum effect of D-serine toxicity is observable within
24-48 h of treatment. The dose of furosemide (10 mg/kg) was based upon studies
showing maximal diuretic effectiveness in rats within 1 hour postdose (69, 70).
Furosemide was expected to exert a minor pressure on kidney activity, thus helping to
detect any weakness in kidney function. The use of furosemide in this study is analogous
to the glucose tolerance test performed in diabetes screenings. As the glucose is given as
the metabolic challenge and the body’s ability to clear the glucose from the blood reflects
to which extent the body is normally functioning. Furosemide was expected to expose the
ability of kidney in handling a D-serine dose characterized as a non-harmful dose.

7

Figure 2. Chemical Structure of furosemide with corresponding proton numbering

8

2. MATERIALS AND METHODS
The protocols for handling laboratory animals were approved by the WrightPatterson Institutional Animal Care and Use Committee (IACUC), and all animal
experiments were conducted in accordance with federal guidelines. Furosemide was
purchased from Webster Veterinary, Columbus, OH and D-serine was from SigmaAldrich. Both compounds were prepared in 0.9% sterile saline solution (vehicle).
Male Sprague-Dawley rats (200 – 225 g) were purchased from Charles Rivers
Laboratories (Raleigh, NC) and were quarantined (3 days) and allowed to acclimate to
housing conditions involving a 12 h light-dark cycle at 25 °C with ad libitum access to
food and water. At 4 days prior to the start of the study, animals were randomly assigned
to one of four experimental groups (N=12/group) and housed individually in metabolism
cages.
2.1 Experimental Design
The experimental design involved two intraperitoneal (IP) injections (10 ml/kg)
separated by 24 h, and all animals were also fasted during this 24 h period (Figure 3).
We chose to fast animals in order to establish a more consistent metabolic state and
minimize effects due to random feeding among animals; all animals were provided ad
libitum access to water during the fasting period. Metabolism cages were fitted with 50
9

ml urine collection tubes containing 1 ml of 1% sodium azide, and maintained at 6–10 °C
using I-Cups (Bioanalytical Systems, Inc., West Lafayette, IN). Three baseline urine
samples were collected prior to the administration of dosing solutions (at -48, -24 and 0
h), and daily thereafter. All urine samples were stored at -80 °C until subsequent
preparation for NMR analysis. On days involving treatments, urine was always collected
prior to IP injection of animals. For the first injection at t=0, animals were given vehicle
(Ve) or 60 mg/kg D-serine (Ds), while the second injection at 24 h involved vehicle or 10
mg/kg furosemide (Fu). The four experimental groups are designated by those treatments
in which animals received vehicle alone (VeVe), furosemide alone (VeFu), D-serine
alone (DsVe), or D-serine + furosemide (DsFu).

Figure 3. Schematic diagram of the experimental design depicting times of treatments
(arrows) and urine collections (U). See text for details.

10

2.2 Sample Preparation
Frozen urine samples were thawed at 4 o C overnight. A 600 l aliquot of urine
was then mixed with 300 l of phosphate buffer (0.2 M mono- and disodium phosphate;
pH 7.4) and centrifuged at 13,000 rpm for 10 min to remove any precipitates. A 550 l
aliquot of the supernatant was transferred to a 5 mm NMR tube and mixed with 150 l of
2,2’,3,3’–tetradeutero-trimethylsilylpropionic

acid

(TSP) in deuterium oxide (D2 O),

adjusted to yield a final concentration of 2 mM. The TSP served as a chemical shift
reference ( = 0.00 ppm) and D2 O provided a field-frequency lock for NMR data
acquisition.
2.3 NMR Data Acquisition and Processing
All 1 H NMR spectra were acquired using a Varian INOVA operating at 600 MHz
and probe temperature of 25

o

C. Water suppression was achieved using the first

increment of a NOESY pulse sequence, which incorporated saturating irradiation at the
water resonance frequency during a 2 s relaxation delay (pre-saturation) and again during
a 50 ms mixing time. A total of 128 transients were collected per spectrum using an
acquisition time of 4.0 s and inter-pulse delay of 11.05 s.
Steps involved in 1 H NMR data processing and analyses are outlined in Figure 4.
NMR data were processed using Varian software (VNMR 6.1c) employing exponential
multiplication (producing line-broadening of 0.30 Hz), Fourier transformation, and phase
correction.

Spectra were then baseline corrected (flattened) in MATLAB (The

Mathworks, Inc. Natick, MA; v. R2010b) using the Whittaker Smoother algorithm (with
11

lambda value of 200) on selected spectral noise regions (71, 72). Quantification of
specific

metabolite

resonances

was

accomplished

using

an

interactive

spectral

deconvolution algorithm in MATLAB adapted from our previously described methods
(73).

The deconvolution tool fits a defined spectral region using a combination of

tunable baseline shapes (spline, v-shaped, linear, or constant) and a Gauss-Lorentz peakfitting function. Integrated areas for peaks of interest are then output to a text file.

12

Figure 4. Steps involved in 1 H NMR data processing and analyses
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Spectral processing for multivariate data analyses included removal of regions
containing resonances from TSP (at 0.0 ppm), water (4.72 – 5.00 ppm), and urea (5.54 –
6.01 ppm). We also removed the spectral regions containing resonances from serine (3.82
– 3.86 and 3.92 – 4.01 ppm; (74) and preliminary studies in our laboratory), since Dserine was administered to some animals and was expected to be excreted in urine. The
peak intensities for the remaining metabolite signals of each spectrum were then summed
to a constant value (sum normalized). To reduce the dimensionality and mitigate peak
misalignment, a dynamic programming-based adaptive binning technique was employed
(73) using a minimum and maximum distance between peaks in a single bin of 0.001 and
0.04 ppm, respectively. Bin boundaries were then manually adjusted to further mitigate
peak misalignment, and to keep known J-coupled multiplets within that same bin (e.g.,
doublets, triplets, etc). Data were then autoscaled using various datasets as reference
depending upon which metabolic effects were being investigated (see below).
2.4 Multivariate Data Analyses
Multivariate data analyses were conducted on binned, scaled spectral data using
MATLAB software. Binned NMR data were scaled to a chosen reference dataset by
subtracting each bin value from the mean value for the corresponding bin in the reference
data, then dividing this value by the standard deviation of the reference data (autoscaling).

The reference data for auto-scaling was chosen to emphasize specific effects

(details are given in Results).
Unsupervised Analysis. Principal Component Analysis (PCA) provided a firstapproach, unsupervised technique for data visualization. As previously described (75),
14

our analysis tools enable us to construct a PCA model based on specific experimental
groups, and then apply the model-specific bin coefficients to other data groups to
visualize these data relative to the existing model.

To maximize visualization of specific

responses, we modeled data based upon the nature of the effects being assessed. For
instance, to visualize the effects (trajectory in PCA space) related to furosemide
treatment, a PCA model comprising data from the furosemide-treated group (VeFu) and
control group (VeVe) at all time points was constructed. Coefficients generated in this
PCA model could then be applied to other groups (DsVe and DsFu) to create a trajectory
into the latent vector space relative to the patterns created by the groups in the model
(75). PCA scores plots were employed to help identify the time points of maximum
effects for treatments.
Supervised Analysis.

Orthogonal Projections onto Latent Structures Discriminant

Analysis (OPLS-DA) was used to classify data and identify salient features that
distinguish the various treatment and control groups. In order to apply OPLS-DA,
spectral data are collected into a matrix of variables or bins (X) and a vector of
categorical labels (Y), representing the effects. For these data, the categorical labels were
treatment and time (e.g., DsFu, 48 h post-dose). These data were analyzed and modeled
as follows: (1) determine a specific time point of interest (e.g., 48 h post-dose); (2)
encode each treatment and corresponding control group as a two-group problem and
analyze with OPLS (e.g., 1 = DsFu, 48 h post-dose; 2 = VeVe (control), 48 h postvehicle); (3) using the model created for this specific two-group problem, project the
remaining samples from other groups into the OPLS model.

15

Statistical Evaluation of OPLS Results. The OPLS model was evaluated on its
predictive ability, using the Q 2 (coefficient of prediction) metric.

Q 2 was calculated as

follows:
n

Q2 1

PRESS
1
SSY

y

i

 yˆ i 

i

 yi 

2

i1
n

y

2

i1

where PRESS is the Predicted REsidual Sum of Squares calculated as the residual e

 between the predicted and actual Y (class labels) during leave-one-out cross-validation,
SSY is the Sum of Squares for y, y is the y mean across all samples, and ŷi is the y value
for sample i. As Q 2 approaches 1, the more predictive capability the model exhibits. A
Q 2 value less than zero 
indicates that the model has no predictive power. A permutation
test was performed to evaluate the significance of the Q 2 metric.

The test involved

repeatedly permuting the data labels and re-running the discrimination analysis, resulting
in a distribution of the Q 2 scores (76). The Q 2 from the correctly labeled data is then
compared to the distribution to determine the significance of the model at a specified
alpha (set herein at α = 0.01).
Variable

selection

(salient

bins)

from

OPLS-DA

was

also

statistically

evaluated. The bin loadings, commonly referred to as coefficients, were compared to
calculated null distributions in order to select for significance. The null distribution for
each bin was determined by refitting the OPLS model to datasets in which each bin was
independently and randomly permuted to remove any correlation between it and the
control/treatment groups. The true OPLS model loading was then compared to the
resulting null distribution of loadings, and values in the tail (greater than 99.5% or less
16

than 0.5% of the null distribution; corresponding to alpha = 0.01) were assumed to
contribute significantly to the model. The permutation was initially repeated 500 times
for each bin and those near-significant loadings (greater than 92.5% or less than 7.5% of
the null distribution; corresponding to alpha = 0.15) were selected for 500 additional
permutations (total 1000).
2.5 Qualitative assessment of effects related to fasting and re -feeding
The control group (VeVe) was used to assess the metabolite changes inherent to
fasting and re-feeding. Effects of fasting and re-feeding were assessed by comparing the
urinary spectral intensities obtained from urine samples collected at time 0 h (reference)
to those collected at 24 h (post fasting) and 48 h (24 h post re-feeding) respectively. Data
for the reference time point (0 h) and data for fasting or re-feeding were included in the
supervised OPLS-DA (see details in the section on multivariate analyses) model to
generate salient features (bins) that classify the two times. Then the NMR spectra from
the time point of reference and those for fasting or re-feeding were superimposed using
MATLAB software (The Mathworks, Inc. Natick, MA; v. R2010b). This assessment was
conducted on sum normalized spectral data. Spectra for these two time points that were
being investigated were identified by different colors. Then, their spectral intensities in
each bin were qualitatively compared. The peak intensities for the time point of interest
(fasting or re-feeding) was scored as decreasing or increasing relative to the referenced
time (0 h).

17

3. RESULTS
3.1 Metabolic response to fasting and re-feeding
Urine samples were collected daily from 48 Sprague-Dawley rats (4 experimental
groups with N=12/group) for a period of 7 days (see Fig. 3). Serial changes in the mean
urinary volume outputs for each experimental group are shown in Figure 5. Urine output
at predose times (-48, -24, and 0 h), and at 72 h and 96 h are similar among all groups.
Fasting, however, produced a significant increase in urine output (observable at 24 h),
which returned to baseline levels within 24 h of re-feeding (observable at 48 h). A twoway repeated measures ANOVA (treatment and time as factors) and Tukey posthoc test
(p ≤ 0.05) was used to analyze volume changes between predose (represented by the
average of -48, -24, and 0 h data), 24 h and 48 h time points. Volume output for all
groups at 24 h was significantly increased relative to predose (p ≤ 0.05). This effect, due
to fasting, has also been reported by others (77). For animals not receiving furosemide
(VeVe and DsVe), urine output returned to baseline levels by 48 h (within 24 h of refeeding).

Animals dosed

with furosemide (DsFu and

VeFu), however, showed

significantly higher urine output at 48 h (24 h post furosemde treatment) in comparison to
the control group (VeVe) (p ≤ 0.05). Thus furosemide was an effective diuretic drug at
the dose used in this animal model.

18

Figure 5. Changes in 24 h-urinary volume output (Mean ± SD; N=12/group) from Sprague-Dawley rats during the
experimental protocol diagramed in Figure 3. Data at predose (average of -48, -24, and 0 h time points), 24 h and 48 h were
analyzed by a two-way repeated measures ANOVA and Tukey HSD posthoc test. Within-group significant differences (p ≤
0.05) are denoted by “a” (different from predose) and “b” (different from predose and 48 h). Groups that are significantly
different from the control group (VeVe) at 48 h are denoted by “c” (p ≤ 0.05).
19

Unsupervised PCA models depicted in Figures 6 and 7 indicate a common
clustering of all the groups at 24 h post fasting. However, this clustering of groups was
separate from the mapping positions at the pre-dose times, depicting the metabolite
changes that are attributable to fasting conditions. The greatest separation in data was
observed between pre- and post-fasting times (t=0 and t=24 h, respectively) as well as
between 24 h and 48 h (24 h post re-feeding). These also were the periods within which
the highest urinary outputs were collected. As the increase in urine volumes is translated
into an excretion of diluted metabolites, the metabolic changes associated with fasting
and furosemide treatment may be broader in scope and modest in magnitude.
To assess the effects of fasting and re-feeding on the metabolite changes, two
OPLS-DA models were performed using the control (VeVe) data (Table 1). The first
model evaluated the effects of fasting by comparing the data collected at time 0 h (prior
to fasting) to data for the 24 h time point (post fasting) and the model was significant (Q 2
= 0.93; α = 0.01; accuracy = 96). Impact of re-feeding on the metabolite alterations was
assessed in a model that compared data obtained at 0 h (baseline) to those collected at 48
h (post re-feeding) and it was significant (Q 2 = 0.95; α = 0.01; accuracy = 100).
Metabolites in the significant bins that were generated by the two OPLS-DA models are
listed in Table 1 along with information about their intensity changes. Our study has
documented a considerable range of metabolites that are decreasing or increasing
following the fasting or re-feeding periods (Table 1). The red arrow indicates an increase
in the metabolite intensities while the black arrow depicts a decrease. Fewer metabolites
(23 metabolites) were out of normal ranges within 24 h post-refeeding period as
compared to metabolites (32 metabolites) that responded to the 24 h fasting period. Out
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of 23 metabolites that were altered relative to the baseline, 20 of them were characterized
by an increase. Similar effects of fasting and re-feeding were characterized by an increase
of

glycolytic

products

(pyruvate

and

lactate),

amino

acids

(alanine

and

isoleucine/leucine), acetate, benzoate, allantoin, phenylacetyglycine and creatinine. TCA
intermediates (citrate and α-ketoglutarate) and hippurate displayed a continuous decrease
(during fasting and re-feeding). Some of the metabolites that were negatively affected by
the fasting displayed an increase inherent to re-feeding. These were malonate, creatinine,
methylguanidine,

3-hydroxyisobutyrate,

trigonelline,

urocanate,

trans-Aconitate

and

homovanillate. Intensity levels of the amino acids such as lysine/arginine and glycine,
glucose,

fumarate,

methylamine,

dimethylamine,

sarcosine,

butaine,

trimethyl amine

oxide (TMAO), choline, taurine and pyridoxine were normalized within the 24 h of refeeding. Although fasting did not have an effect on the urinary levels of formate,
trimethylamine and thymidine, re-feeding induced their increase.
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Table 1. Metabolite changes associated with fasting and re-feeding in control SpragueDawley rats (VeVe group).
Metabolite

Direction of changes relative to baseline (0 h)
post fasting (at 24 h)

post re-feeding (at 48 h)

Glucose

↑

-

Pyruvate

↑

↑

Lactate

↑

↑

Citrate

↓

↓

α-ketoglutarate

↓

↓

Fumarate

↓

-

Alanine

↑

↑

lysine/arginine

↑

-

isoleucine/leucine

↑

↑

Glycine

↑

-

Methylamine

↓

-

Dimethylamine

↓

-

Sarcosine

↓

-

Betaine

↓

-

TMAO

↓

-

Hippurate

↓

↓

Glycolysis

TCA intermediates

Amino acids

Others
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Table 1 – Continued

Malonate

↓

↑

Creatine

↓

↑

Methylguanidine

↓

↑

3-hydroxyisobutyrate

↓

↑

Trigonelline

↓

↑

Urocanate

↓

↑

trans-Aconitate

↓

↑

Homovanillate

↓

↑

Choline

↑

-

Acetate

↑

↑

Taurine

↑

-

Benzoate

↑

↑

Allantoin

↑

↑

Phenylacetylglycine

↑

↑

Pyridoxine

↑

-

Creatinine

↑

↑

Formate

-

↑

Trimethylamine

-

↑

Thymidine

-

↑

↑ Increase
↓ Decrease
- No change
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3.2 Metabolic response to D-serine and furosemide treatments
Figure 6 shows a PCA scores plot (PC1 vs PC2) that models all groups (VeVe,
DsVe, VeFu, DsFu) at all time points (-48, -24, 0, 24, 48, 72, 96 h). Data were autoscaled
using all groups at pre-dose times (-48, -24, 0 h) as reference. Trajectories across time are
mainly due to fasting (at 24 h) and re-feeding (at 48 h) effects, but data return to the
predose position by 96 h (data at 72 and 96 h are omitted in the plot for clarity). All
groups respond equally to fasting as evidenced by a common clustering at 24 h. The
control (VeVe) and DsVe groups display similar mapping position at all times, indicating
no observable effect of D-serine treatment in the absence of furosemide. Interestingly, at
48 h slight differences are observed in mapping positions between groups, which
presumably reflect changes in urinary metabolite profiles that are induced by furosemide
and a combination of D-serine/furosemide treatments (VeFu and DsFu groups).
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Figure 6. PCA scores plot (PC1 vs. PC2 representing 41% of total variance) based on rat
urinary NMR spectra from functional metabolomics study. Symbols and ellipses are
centroid mean ± 2SE; arrows show trajectories across time. Data were autoscaled (see
Methods) relative to all pre-dose time points (-48, -24, 0 h), and the PCA model includes
all groups at all time points. Data at 72 h and 96 h are not shown for clarity but follow a
trajectory towards the pre-dose times.
Although the D-serine/furosemide and furosemide-induced effects are observable
at 48 h, they are not fully exposed by this PCA model due to the overwhelming impact of
fasting/re-feeding animals. In order to suppress the impact of fasting and highlight the
effects that are attributable to treatments, data were autoscaled relative to VeVe + VeFu
groups at 24 h (corresponding to the time of maximum effects due to fasting and
including only animals receiving vehicle solution; note: furosemide was administered
after the 24 h urine collection). A PCA model based on these groups (VeVe + VeFu)
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across all time points (autoscaled relative to 24 h) is shown in Figure 7. Data from DsVe
and DsFu groups were superimposed in the plot using coefficients derived from the PCA
model. Clustering of the groups at predose and 24 h times is apparent, similar to the
results observed in Figure 6 and, as expected, suppressing the effects of fasting resulted
in better separation between animals receiving furosemide versus vehicle (VeFu and
DsFu vs. VeVe and DsVe) observed at 48 h. Moreover, the model does not display any
difference in mapping positions between the control (VeVe) and DsVe groups, again
indicating the lack of observable effects from D-serine treatment.

Figure 7. PCA scores plot (PC1 vs. PC2 representing 49% of total variance) based on rat
urinary NMR spectra for VeVe + VeFu groups at all time points, with data autoscaled
(see Methods) to these same groups at 24 h. Data from DsVe and DsFu groups were
26

superimposed in the plot using coefficients derived from the PCA model. Symbols and
ellipses are centroid mean ± 2SE; arrows show trajectories across time. Data at 72 h and
96 h are not shown for clarity but follow a trajectory towards the pre-dose times.
Effects due to D-serine and furoseamide treatments should be apparent at 48 h,
thus we used PCA to model these groups together with the control group (VeVe) at 48 h,
and autoscaled these data relative to VeVe at 48 h to minimize effects due to re-feeding.
Groups not included in the model were superimposed in the PCA scores plots (Figure 8)
using the coefficients derived from the PCA model. Figure 8A and 8B show good
separation between animals receiving furosemide versus vehicle along PC1 (VeFu and
DsFu vs. VeVe and DsVe). Again the VeVe and DsVe groups overlap as expected, but
the groups receiving furosemide alone versus a combination of D-serine + furosemide
show an emerging separation at 48 h, particularly in Figure 8A.
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Figure 8. PCA scores plots modeling (A) VeVe + VeFu at 48 h (PC1 vs. PC2 representing 54% of variance), and (B) VeVe +
DsFu at 48 h (PC1 vs. PC2 representing 39% of variance). Data for DsVe and DsFu at 48 h are superimposed in plot A, while
data for DsVe and VeFu are superimposed in plot B using coefficients derived from the PCA models. All data were autoscaled
(see Methods) relative to VeVe at 48 h, and symbols and ellipses are centroid mean ± 2SE.
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OPLS

discriminant

analyses

were

conducted

to

evaluate

the

statistical

significance and identify the salient features (spectral bins) that are associated with group
classification at 48 h. The model significance was tested at α = 0.01 and the results,
displayed in Figure 9 (T vs. T Orthogonal plots), clearly show that animals receiving
furosemide alone (VeFu) or D-serine + furosemide (DsFu) are significantly different
from vehicle-treated controls (VeVe) (Fig. 9A and 9B). Indeed, the Q 2 values were ≥0.90
and the predictability accuracy for both models was 100% (leave-one-out cross
validation). A total of 69 and 43 significant bins (α = 0.01) were derived from VeVe vs.
VeFu and VeVe vs. DsFu OPLS-DA models, respectively. An OPLS-DA for VeFu vs.
DsFu at 48 h also yielded a significant result (Q 2 = 0.44; Accuracy = 100%) and
generated 23 salient bins responsible for group classification (Fig. 9C).

In a further

analysis, we tested for correlation between the coefficients for these 23 significant bins
found by OPLS-DA (Fig. 9C) and the loadings for principal component 1 from the PCA
displayed in Fig. 5A, which showed a slight separation between VeFu and DsFu groups.
Interestingly, Spearman’s Rank Correlation showed these coefficients to be highly
correlated (Spearman || = 0.7194; p = 0.0001) indicating that the unsupervised PCA and
supervised OPLS-DA models are finding similar features to classify the effects of
furosemide alone (VeFu) and a combination of D-serine + furosemide (DsFu). In each of
the OPLS model plots shown in Figure 9, we superimposed data from the other groups
not included in the model. As expected, VeVe and DsVe were clustered together similar
to the PCA results. Additionally, an OPLS-DA for VeVe vs. DsVe was not significant
(Q 2 = 0.012; p = 0.01), confirming that no significant effects from D-serine treatment
alone were observable.
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All the significant bins derived from the three OPLS-DA models (Fig. 9A, 9B and
9C) are shown in a Venn diagram (Fig. 9D) to illustrate the number of common and
unique features derived from these models.

Figure 10 depicts all the combinations of

OPLS-DA models used in the extraction of the salient features that classify the VeVe,
VeFu and DsFu groups. The analyses that classify and separate VeFu from VeVe (Fig.
9A) and DsFu from VeVe (Fig. 9B) yield 86 distinct bins, 26 of these are shared
(identical bins) between the two models (Fig. 10).

Presumably, these 86 bins are

important for the classification of VeFu, DsFu and VeVe. Therefore, we conducted
analyses similar to those presented in Figure 8, but used only these 86 significant bins as
input to PCA. These PCA scores plots (data not shown) appear similar to those in Figure
8, which used all 267 spectral bins in the PCA models. Focusing on the clustering
observed for VeFu and DsFu at 48 h, with an aim towards determining which bins are
responsible for group classification, we again conducted OPLS-DA. An OPLS-DA model
for VeFu vs. DsFu at 48 h using this limited set of 86 bins (OPLS scores plot not shown)
is statistically significant (Q 2 = 0.51; accuracy = 96%) and yields 23 significant bins
[shown in Fig. 10 as (B)] when the model significance is tested at α = 0.01.

Ten of these

23 bins are common (identical) to a set of bins that are derived from the same model, but
using all 267 spectral bins [shown in Fig. 10 as (A)]. In other words, each of the two
models (OPLS using 267 bins and OPLS using 86 bins as input) generates 13 unique
features in addition to 10 shared features, yielding a total of 36 bins that drive the
separation of VeFu and DsFu at 48 h (Fig. 10).
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D

Figure 9. OPLS-DA models using rat urinary NMR spectra at 48 h with all data autoscaled to the control group (VeVe) at 48
h. (A) VeVe vs. VeFu (Q 2 = 0.95); (B) VeVe vs. DsFu (Q 2 = 0.90); and (C) DsFu vs. VeFu, (Q 2 = 0.44). Models A, B, and C
are all statistically significant (test α = 0.01; see Methods) and yield an accuracy of 100% (leave-one-out validation). Large
symbols depict data from the modeled groups, while other groups superimposed in the model are shown in smaller symbols.
The number of significant bins determined by the OPLS-DA model (α = 0.01; see Methods) is indicated in each plot, and also
displayed in a Venn Diagram (D).
31

Figure 10. Diagram that depicts all the combinations of OPLS-DA models used in the
extraction of the salient features that classify the control (VeVe), furosemide (VeFu) and
D-serine + furosemide (DsFu) groups at 48 h.
Taken together, we find a total of 26 bins that are important for classifying VeFu
and DsFu groups separately from vehicle control (VeVe) and an additional 36 features
that are important for separating VeFu and DsFu groups at 48 h (see Fig. 10). Figure 11
shows PCA scores plots (PC1 vs PC2) based on a combination of all these features (26 +
36 = 62 bins; Fig. 11 A) and a total of 267 bins (Fig. 11 B). The PCA models include
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VeVe + VeFu + DsFu at 48 h. The model constructed using 62 bins (Fig. 11 A) shows a
clear distinction between VeVe, VeFu and DsFu groups. But when the DsVe group is
superimposed in this model, these data overlap with the control group (VeVe).

Thus

there is a lack of observable effects from D-serine treatment alone, but in combination
with furosemide distinct metabolic changes are observable that appear to be associated
with 36 features. These 36 features may represent the salient urinary metabolite changes
that reflect mild kidney dysfunction induced by exposure to low-dose D-serine. A
comparison between the PCA scores plot shown in Figure 11 A to the PCA scores plot
generated using all the 267 spectral bins (Fig. 11 B) indicates that a clear classification of
the groups is obtained when the PCA model is based on a selection of 62 bins.
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Figure 11. PCA scores plots modeling VeVe + VeFu + DsFu groups at 48 h with data autoscaled (see Methods) relative to
VeVe at 48 h. (A) the PCA model uses a total of 62 bins selected by OPLS-DA (see text for details; PC1 vs. PC2 representing
59 % of total variance). (B) the PCA model uses all 267 spectral bins (PC1 vs. PC2 representing 43 % of total variance). Data
from the DsVe group are superimposed in both plots using coefficients derived from the PCA models.
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NMR spectral regions identified as significant by OPLS-DA were compared
between experimental groups, and specific resonances were assigned to metabolites with
the aid of literature, on-line databases (HMDB, http://www.hmdb.ca/), and Chenomx
NMR Suite software (Edmonton, Alberta, CA).

We analyzed the 36 significant bins

derived from the OPLS-DA that emphasize the effects of D-serine observable in the
presence of furosemide (VeFu vs. DsFu at 48 h). From these 36 bins we assigned 11
unique independent metabolites (some bins contained redundant information since
multiple peaks were detected from the same metabolite) plus one additional signal that
could not be identified. These 12 metabolite signals were quantified (integrated peak
areas) using a spectral deconvolution/peak-fitting algorithm (see Methods). It is important
to note that, because of the sum normalization procedure (see Methods), metabolite
intensities are represented as a fraction of the total urinary metabolite pool in each
sample. Table 2 displays these metabolite data expressed as a ratio of the treatment group
(VeFu or DsFu) relative to control (VeVe) at 48 h. Table 2 also differentiates those data
determined to be statistically significant by OPLS-DA for specific treatment vs. control
groups, and those found to be significant when analyzed by peak integration and t-test
(superscripts a and b, respectively). Relative to the control group (VeVe), furosemide
treatment alone (VeFu) caused a ca. 2-fold increase in lactate, glucose, and choline, and a
30% decrease in citrate. These effects appear to be mitigated in the group exposed to Dserine prior to furosemide (DsFu) and, instead, this group shows a 1.7-fold increase
(relative to VeVe) in a doublet signal at 6.83 ppm, which is characteristic of aromatic
protons on a para-substituted phenol. This metabolite is likely to be a p-phenolic acid
derivative of tyrosine such as 4-hydroxyphenylpropionic acid (desaminotyrosine), 435

hydroxyphenylpyruvic

acid

(HPPA),

or

4-hydroxyphenyllactic

acid

(HPLA).

Desaminotyrosine seems an unlikely candidate since its source is microbial (gut
microbial metabolism of tyrosine). Figure 12 shows the tyrosine metabolism pathway that
generates the HPPA and HPLA compounds.

These compounds are produced in kidney

by transamination of tyrosine via tyrosine aminotransferase to yield HPPA, which can be
reduced to HPLA by 4-hyrdroxyphenyllactate dehydrogenase. Others have also observed
these metabolites in NMR spectra of rat urine under experimental conditions involving
perturbations to the tyrosine catabolism pathway (20, 78). We could not unequivocally
assign this metabolite since resonances from its aliphatic protons were obscured in
densely populated regions of the spectrum. Therefore, we will refer to this metabolite as a
p-phenolic acid derivative of tyrosine (PAdY).
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Table 2. Changes in 12 urinary metabolites (U, unidentified) identified from 36
significant bins (some metabolites yielded signals in multiple bins) derived from OPLSDA for comparisons between experimental groups at 48 h (see text for details). Values
are reported as a fold-change ratio for treated (VeFu or DsFu) versus control (VeVe)
groups. Peak multiplicities are indicated as: s, singlet; d, doublet; dd, double of doublet;
t, triplet. Standard rules for propagation of errors were used to determine the ±SE for
calculated ratios.

Metabolite

Chemical
Shift in ppm

Fold Change (Mean ± SE)
VeFu/VeVe
DsFu/VeVe
ratio
Ratio

Lactate

1.33 (d)

2.2 ± 0.6 a, b

1.2 ± 0.2 a

Glucose

4.66 (d)

1.7 ± 0.3 a, b

1.3 ± 0.2 a

Choline

3.20 (s)

1.6 ± 0.2 a, b

1.3 ± 0.1 a, b

Tyrosine

3.16 (d)

1.2 ± 0.1 a

1.1 ± 0.1 a

PAdY 1

6.83 (d)

0.9 ± 0.2 a

1.7 ± 0.3 b

Phenylacetylglycine

7.36 (t)

0.9 ± 0.1 a

1.2 ± 0.2 a

Homovanillate

6.76 (dd)

0.9 ± 0.1 a

1.1 ± 0.1 a

Unknown

7.46 (s)

0.9 ± 0.1 a

0.9 ± 0.1

Citrate

2.55 (d)

0.7 ± 0.1 a, b

1.0 ± 0.1

Dimethylglycine

2.93 (s)

0.7 ± 0.2 a

0.8 ± 0.2

Tryptophan

7.22 (t)

0.7 ± 0.1 a

0.8 ± 0.1 a

histidine + N,N-methylhistidine1

7.07 – 7.05

0.7 ± 0.1 a

0.9 ± 0.1

1

A p-phenolic acid derivative of tyrosine (see text for details).
Significant bins from OPLS-DA for each specific treatment group vs. control (Q 2 ≥
0.90; p ≤ 0.01).
b
Significant difference in treated vs. control for quantified metabolite signal (t-test, p ≤
0.05).
a
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We also measured metabolite ratios within each urine sample for the VeVe, VeFu,
and DsFu groups at 48 h (Table 3). We focused on those metabolites deemed important
via OPLS-DA procedures and based ratios relative to the urinary creatinine level, or
between metabolites that share a common pathway (e.g., homovanillate/tyrosine;
PAdY/tyrosine; glycine + dimethylglycine/choline). In general, amino acids (represented
as: tyrosine + tryptophan + histidine + N,N-methylhistidine) are decreased in the VeFu
and DsFu groups relative to the vehicle control group (VeVe). Furosemide alone (VeFu)
also caused a decrease in the citrate/creatinine ratio relative to the VeVe group.
Therefore, we chose to measure other TCA (tricarboxylic acid cycle) metabolites that
-ketoglutarate (2.45 ppm), succinate (2.41
ppm), and fumarate (6.53 ppm). The sum of these TCA inte

-

ketoglutarate + succinate + fumarate) expressed as a ratio to creatinine was also
significantly decreased in the VeFu group relative to control. These metabolite ratios,
however, were unaffected in the DsFu group. The sum of glycine and dimethylglycine
expressed as a ratio to choline (glycine + dimethylglycine/choline) was also reduced in
the VeFu group relative to control (VeVe), but this ratio was again unaffected in the
DsFu group. Interestingly, the PAdY/tyrosine ratio in the DsFu group was not different
from the control (VeVe) value, but was 2-fold higher in comparison to the VeFu.
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Table 3. Urinary metabolite ratios (Mean ± SE) for VeVe, VeFu, and DsFu experimental
groups measured at 48 h.

Metabolite Ratios

VeVe

VeFu

DsFu

lactate / creatinine

0.5 ± 0.1

0.8 ± 0.2

0.4 ± 0.1

glucose / creatinine

0.3 ±  0.1

0.3 ±  0.1

0.3 ± 0.1

phenylacetylglycine / creatinine

0.2 ±  0.1

0.2 ±  0.1

0.2 ±  0.1

citrate / creatinine

3.2 ± 0.2

1.7 ± 0.2 a

2.4 ± 0.3

21.2 ± 3.0

9.9 ± 1.3 a

19.3 ± 3.1 b

2

0.5 ± 0.1

0.3 ±  0.1a

0.3 ±  0.1 a

glycine + dimethylglycine / choline

8.3 ± 1.0

5.5 ± 0.7 a

6.9 ± 1.0

homovanillate / tyrosine

1.1 ± 0.1

0.8 ± 0.1

1.0 ± 0.1

PAdY / tyrosine

0.3 ±  0.1

0.2 ±  0.1

0.4 ±  0.1 b

TCA intermediates / creatinine

1

Relevant amino acids / creatinine

1 TCA intermediates = citrate + α-ketoglutarate + succinate + fumarate.
2 Relevant amino acids = tyrosine + tryptophan + histidine + N,N-methylhistidine.
a Significantly different from the control (VeVe) group (t-test and Bonferroni correction;
p ≤ 0.05).
b Significantly different from the VeFu group (t-test and Bonferroni correction; p ≤ 0.05).
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4. DISCUSSION
This study combined a tissue-targeted metabolic challenge (stressor) and NMRbased metabolomics to investigate whether this approach could enhance sensitivity to
detect tissue dysfunction. We used an animal model and targeted kidney with a diuretic
stressor (furosemide) and induced mild tissue dysfunction with a known kidney toxicant
(D-serine). The experimental protocol also included a 24-h fasting period in an attempt to
reduce baseline variability in urinary metabolite profiles. Since the main focus of this
study was not to assess the effects of fasting/re-feeding, we did not elaborate on these
effects. Thus, we are reporting here simply the results on the qualitative assessment of
effects related to fasting and re-feeding.
4. 1 Fasting and furosemide treatment mediate an increase in urinary volume
output
Fasting and re-feeding animals induced significant metabolic effects, which
nearly masked our capability to detect changes due to treatments. As seen in Figure 5,
fasting also caused a significant increase in urinary volume output, which is consistent
with previous reports in Sprague-Dawley rats (77, 79). A 2.4-fold increase in urine
volumes was observable in the samples collected from fasted rats relative to the baseline
samples. A 2-fold increase in urine volume for overnight (16 h) fasted Sprague-Dawley
rats has also been documented (77). The mechanism for this fasting-induced urine
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increase is well established and associated with a decrease in renal aquaporin proteins,
and imbalance in the regulation of water reabsorption (79, 80).
As expected, furosemide treatment also caused a transient increase in urinary
output at 24 h postdose (t=48 h in Fig. 5), with levels returning to baseline by the next
urine collection time (t=72 in Fig. 5). The diuretic nature, metabolism and molecular
basis of furosemide have been well characterized (61, 63-65, 70, 81, 82). The target and
mechanism of these effects involves reversible binding of furosemide to luminal
Na+/2Cl– /K+ symporters in the thick ascending limb of the loop of Henle (59-63).
Another portion of the nephron, the proximal tubules, is the target of D-serine
nephrotoxicity.
4. 2 Fasting and re-feeding induce an alteration in urinary metabolite levels
Fasting has been found to be associated with down-regulation of the renal water
channel (aquaporins), thus resulting in a decrease in water reabsorption (79). This
decrease in water re-uptake can explain an increase in urine volumes we observed with
the fasted rats. The current study performed a qualitative assessment of the effects related
to fasting and re-feeding. The study documented a considerable range of metabolite
changes due to fasting and re-feeding. Fasting induced an increase in urinary excretion of
glucose,

pyruvate,

lactate

and

amino

acids

such

as

alanine,

lysine/arginine,

isoleucine/leucine and glycine. An increase in urinary excretion of other metabolites such
as choline, acetate, taurine, benzoate, allantoin, phenylacetylglycine, pyridoxine and
creatinine was also observed following the 24 h fasting period. Several studies have
reported a wide range of metabolic changes that are associated with fasting (77, 83-89).
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Boedigheimer and colleagues (89) have identified fasting as one of the most significant
sources of variation in gene expression levels. Most recently, Robertson and coworkers
(77) showed that fasting of rats produced changes in most of the urine metabolites
detected in NMR spectral profiles, although the magnitude of these changes was
relatively small. Other studies have reported a fasting-induced down-regulation of several
proteins involved in glycolysis in male Wistar rats (90) and mice (88). Lenaerts et al.
(2006) have documented changes in protein expression levels and amino acid metabolism
that were inherent to 24 h fasting effects. They observed a down-regulation of initiation
translation factors, thus suggesting an inhibition of protein synthesis (91). This could
probably explain the increase of amino acid excretion we observed in our study. We also
noted that fasting induced a decrease in certain TCA intermediates such as citrate, αketoglutarate and fumarate and a set of 14 other metabolites as listed in Table 1. A
decrease in TCA intermediates following fasting has also been documented by other
studies (77, 90). Robertson and coworkers (77) have identified alteration in several genes
that encode the TCA cycle enzymes including a decrease of citrate synthase. Currently,
the fasting-induced decrease in TCA cycle intermediates is not well understood. Many of
these TCA intermediates and other metabolites such as acetate, creatinine, hippurate,
lactate, taurine, trimethyl amine oxide (TMAO) are among the metabolite that have been
characterized as “usual suspects”

as they frequently change in response to any treatment

(22). Fewer metabolites (23 metabolites) were out of normal ranges within 24 h postrefeeding. Most of them (20 metabolites) were characterized by an increase in intensity.
Only three metabolites (citrate, α-ketoglutarate and hippurate) displayed a continuous
decrease. The differences in normalization of metabolites after a period of fasting may
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reflect the differential enzymatic adaptations to re-feeding. Studies have demonstrated
that the rates of glucose metabolism are enhanced during re-feeding (92-95). However,
the energy restoration may depend upon carbohydrate absorption since it has been
demonstrated that an inhibition of carbohydrate absorption in male Sprague-Dawley rats
correlates with a delay in the energy accumulation following re-feeding (96).
4. 3 Low-dose D-serine effects are only observable in metabolically stressed kidney
In this study, D-serine was used to mildly compromise kidney function. Studies
have shown that the maximum effect of D-serine toxicity as manifested in rat urinary
metabolite profiles is observable within 24 – 48 h post-exposure at doses ≥100 mg/kg,
with non-observable effects for doses ≤ 62.5 mg/kg ((21), and unpublished data from our
laboratory). Based upon these previous studies, the selected sub-acute D-serine dose (60
mg/kg) in the current study was not expected to cause any observable effects in normal
healthy rats.
showed

no

This outcome was confirmed. D-serine treatment alone (DsVe group)
significant changes in urinary metabolite profiles in comparison to

corresponding controls (VeVe group) when examined by PCA or OPLS-DA (Figs. 6-10).
The goal of this study was to test whether this functional metabolomics approach
can enhance the sensitivity of NMR-based metabolomics to detect slight changes in
kidney function that may only be detectable under a metabolically stressed condition.
Thus we focused on extracting the urinary metabolite changes that are unique in
classifying the VeFu and DsFu groups. Interestingly, PCA and OPLS-DA models
generated distinct mapping positions for the VeVe, VeFu, and DsFu groups at the 48 h
time point. This time corresponds to 48 h post D-serine and 24 h post furosemide
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treatment. These differences in mapping positions support our hypothesis that D-serineinduced

temporal metabolite changes are observable only when the kidney is

metabolically stressed. Most importantly, we find that the significant features (bins)
leading to separation between the VeFu and DsFu groups, as derived from a supervised
OPLS-DA, are highly correlated with the loadings from an unsupervised PCA
(Spearman’s Rank; p = 0.0001). Thus supervised and unsupervised analyses found
similar variables that are important for group classification. Through a step-wise
progression of multivariate data analyses, we identified 36 significant bins derived from
the OPLS-DA models that appear to be associated with D-serine-mediated disruption of
kidney function. A detailed spectral analysis assigned these changes to 12 metabolites
that are influenced by treatments (furosemide alone or D-serine + furosemide). In normal
functioning kidney, furosemide caused a significant increase in glucose, lactate, and
choline, and a decrease in citrate (Table 2; VeFu/VeVe ratio). But in rats exposed to Dserine in combination with the metabolic stress associated with furosemide (DsFu group),
all of these metabolite changes were abolished, with the exception of choline (Table 2;
DsFu/VeVe ratio). These results suggest that D-serine disrupted, or mitigated, the normal
response to furosemide. The glycine+dimethylglycine/choline ratio was also significantly
reduced by furosemide treatment (Table 3), an effect not observed in the DsFu group
(these metabolites share a common pathway).
With regard to effects on glucose, others have also reported a furosemide-induced
increase in glucose excretion in rats (97-100), mice (101), human (98, 102), and cell-free
preparations obtained from rabbit kidney (98). Jacobs, et al. (100) have suggested that
this effect of furosemide may involve inhibition of glucose transport through a direct
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inactivation of its carrier proteins. Whatever the cause of this effect on glucose excretion,
it is mitigated by low-dose D-serine exposure (i.e., not observed in the DsFu group).
Urinary metabolite ratios were also calculated for glucose, lactate, citrate, TCA
intermediates, and several amino acids (termed relevant amino acids) that were found to
be important (by OPLS-DA) for detection of any functional abnormalities of kidney
induced by D-serine. These metabolite ratios were measured relative to creatinine, as
urinary creatinine clearance has been regarded as an indicator of renal injury (103, 104),
and creatinine was not among the significant features found by our OPLS-DA models.
Citrate and TCA intermediates, whether measured relative to the total urinary metabolite
pool (Table 2) or expressed relative to creatinine (Table 3), were decreased by
furosemide treatment alone but were unaffected in the DsFu group. Thus this furosemideassociated metabolic effect appears to be mitigated by D-serine (observable only when
the kidney is metabolically stressed by furosemide). Although lactate and glucose were
increased by furosemide when expressed as a fraction of the total urinary metabolite pool,
the lactate/creatinine and glucose/creatinine ratios were not different from controls. This
prompted us to measure the stability of creatinine within these experimental groups.
Indeed, treatment caused a significant increase in creatinine relative to controls
(VeFu/VeVe = 1.3 ± 0.1 and DsFu/VeVe = 1.5 ± 0.2; Mean ± SE, p ≤ 0.001), but these
changes in creatinine were not found to be a significant feature for OPLS-DA group
classification. Reports regarding creatinine clearance in patients receiving furosemide
treatment vary (66, 68, 105), and creatinine has been listed among the “usual suspects”
that can frequently change in response to xenobiotics (4). Nonetheless, it is instructive to
consider these data,

particularly the TCA intermediate/creatinine ratio, which is
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significantly reduced in the VeFu group relative to VeVe or DsFu. These results
emphasizes the importance of the effects observed for citrate and TCA intermediates, as
these metabolites are not affected in the DsFu group even though creatinine levels
significantly rise in this same group. Thus D-serine exposure impacts urinary excretion of
TCA intermediates — an effect that is only observable when the kidney is metabolically
challenged with furosemide. These results are interesting in light of the effects of Dserine nephrotoxicity observed at higher doses (≥100 mg/kg) (21), which include
increased urinary excretion of glucose and lactate, and decreases in TCA intermediates
(similar to that seen here with furosemide treatment alone). Thus the metabolite
perturbations expected with high-dose D-serine alone (toxic dose) or furosemide alone,
are suppressed in rats receiving low-dose D-serine followed by furosemide challenge. In
contrast, the perturbation on creatinine excretion induced by furosemide (e.g., increased
urinary excretion), was not affected by prior administration of low-dose D-serine. Thus
some metabolic processes were perturbed while others were not, which may be related to
differences in the specific sites of action for D-serine and furosemide in the nephron.
Regardless,

these metabolite perturbations reflect abnormalities in kidney function

imposed by low-dose D-serine, which are only observable when the kidney is stressed by
furosemide.
A significant and unique metabolic effect observed in the DsFu group relates to
the excretion of a p-phenolic acid derivative of tyrosine (PAdY), presumably HPPA
and/or HPLA (Fig. 12). These metabolites of tyrosine degradation have been observed
previously in NMR spectra of rat urine following inhibition of 4-hydroxyphenylpyruvate
dioxygenase (20, 78), the second enzyme in the tyrosine catabolism pathway that
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converts HPPA to homogentisate. Although the PAdY metabolite might also be
desaminotyrosine, we believe this is unlikely since it is produced via deamination of
tyrosine occurring only in gut microbes. Regardless of its origin, a significant increase in
urinary excretion of the PAdY metabolite was only observed in rats exposed to D-serine
and then challenged with furosemide to stress the kidney. The DsFu group showed a 1.7fold increase in PAdY relative to controls (Table 2), and the PAdY/tyrosine ratio was 2fold higher in the DsFu group relative to the VeFu group (Table 3). Urinary excretion of
tyrosine and PAdY in rats receiving D-serine alone was not different in comparison to
vehicle controls (DsVe/VeVe ratio = 1.3 ± 0.2 and 1.1 ± 0.2 for tyrosine and PAdY,
respectively, and the PAdY/tyrosine ratio = 0.2 ± 0.03 and 0.3 ± 0.04 for the DsVe and
VeVe groups, respectively; no significant difference between groups, p ≤ 0.05, t-test).
Thus, furosemide alone or D-serine alone did not affect tyrosine or PAdY urinary
excretion. These results provide evidence that the plasma levels of tyrosine and PAdY are
unaffected by these treatments (albeit we did not measure plasma metabolites),
suggesting that the differences seen in the DsFu group reflect altered kidney function
with regard to tyrosine metabolism, or the excretion of tyrosine and its derivatives. We
speculate that low-dose D-serine induces a minor insult to renal tubules that, when
combined with the additional stress imposed by furosemide, perturbs the clearance of
phenolic acids. Interestingly, Williams, et al. (20) reported a perturbation in the normal
handling of phenolic acids following severe renal damage induced by 250 mg/kg Dserine in rats, which was only observed in the presence of an enzyme inhibitor of tyrosine
metabolism in kidney. In their study, inhibition of 4-hydroxyphenylpyruvate dioxygenase
caused increased production and urinary clearance of phenolic acids (HPPA and HPLA)
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in normal functioning kidney. But following D-serine-induced kidney damage, rats
instead displayed tyrosinuria with minimal excretion of phenolic acids. Thus it is possible
that some perturbation in the normal handling and excretion of phenolic acids also occurs
at a sub-acute dose of D-serine, but this effect is only manifested under an additional
metabolic stress to the kidney (e.g., furosemide). This may represent a unique effect
associated with tubular damage, which would not have been observed without the
functional metabolomics methodology described herein. Further studies would be of
interest to investigate whether the use of phenolic acids as a kidney stressor would be a
more useful and sensitive means to assess kidney function/dysfunction.
One might argue that the effects observed here are unique because they reflect the
combined treatment of D-serine plus furosemide; however, we believe this is unlikely
since the tissue accumulation, injury, and clearance of D-serine is rapid and occurs prior
to administration of furosemide 24 h later. William, et al. (21) reported that maximal
levels of serine were present in the rat kidney within 30 min of dosing and the first signs
of tissue injury appear at about 1 h. Additionally, 17% of the administered dose was
excreted within the first 8 h, and rats showed recovery from D-serine toxicity beginning
at 24 h. Others have also reported rapid urinary clearance of D-serine in rats, with 28%
excreted within 24 h (106). Thus, we believe that the effects observed in our study reflect
abnormalities in kidney function induced by low-dose D-serine, prior to administration of
furosemide. Another matter to consider is possible bias of our experimental design, which
used an optimal timing for D-serine and furosemide dosing. In other words, the maximal
effect of D-serine was expected to occur at 24 h postdose, which was chosen to coincide
with the furosemide challenge. This likely influenced the results since D-serine-related
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effects at this dose are temporal. But this may not be a critical factor that compromises
the utility of the methodology if it is used to screen for persistent tissue abnormalities.
Further studies are necessary to investigate the relationship between tissue function and
the timing of the metabolic challenge.

Figure 12. The tyrosine catabolism pathway
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5. CONCLUSIONS
By combining a kidney-targeted metabolic challenge (tissue stressor) with urinary
metabolomics analyses, we demonstrated enhanced sensitivity for detection of functional
abnormalities in kidney that may be attributed to low-dose D-serine exposure. In
summary, D-serine mitigated effects of furosemide on urinary excretion of glucose,
lactate, and TCA intermediates. And D-serine caused a unique effect on tyrosine
metabolism that was not observable in the absence of the stress imposed by furosemide.
Although this functional metabolomics approach was limited to kidney, and used a very
specific means to compromise kidney function (exposure to a nephrotoxin), our results
are encouraging and can potentially be extended to other organ systems and functional
abnormalities (i.e., disease pathophysiologies).
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